Pharmacogenomics of schizophrenia: Towards personalized psychiatry

David Gurwitz*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Psychiatry is among the primary medical disciplines to focus on the potential benefits from the cloning of the human genome and the subsequent implementation of personalized medicine. This viewpoint reflects the evident difficulties of current psychiatric practice compared with other disciplines, most notably the limited understanding of disease etiologies, the lack of reliable and objective diagnostic tools, and the paucity of relevant animal models. These aspects of psychiatry face major changes as a consequence of the recent identification of several schizophrenia risk genes. The reviews presented in this issue illustrate the potential for innovative drug discovery and personalized pharmacotherapy for schizophrenia.

Original languageEnglish
Pages (from-to)71-74
Number of pages4
JournalDrug Development Research
Issue number2
StatePublished - 1 Oct 2003


  • D-amino acid oxidase inhibitors
  • D-cycloserine
  • D-serine
  • Glutamatergic hypofunction
  • NMDA receptors
  • Personalized medicine
  • Schizophrenia


Dive into the research topics of 'Pharmacogenomics of schizophrenia: Towards personalized psychiatry'. Together they form a unique fingerprint.

Cite this